Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Bellevue Group AG

Bellevue Group AG lessened its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 1.0% in the 1st quarter, Holdings Channel reports. The fund owned 1,220,085 shares of the company’s stock after selling 12,293 shares during the quarter. Bellevue Group AG’s holdings in Castle Biosciences were worth $27,025,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. RiverPark Advisors LLC boosted its holdings in shares of Castle Biosciences by 362.2% during the 1st quarter. RiverPark Advisors LLC now owns 2,861 shares of the company’s stock worth $63,000 after purchasing an additional 2,242 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Castle Biosciences by 351.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,110 shares of the company’s stock worth $67,000 after buying an additional 2,421 shares during the last quarter. Assetmark Inc. boosted its stake in Castle Biosciences by 21.3% during the fourth quarter. Assetmark Inc. now owns 4,736 shares of the company’s stock worth $102,000 after buying an additional 832 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Castle Biosciences by 943.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 5,739 shares of the company’s stock valued at $124,000 after buying an additional 5,189 shares in the last quarter. Finally, WuXi AppTec Co. Ltd. purchased a new position in shares of Castle Biosciences during the 4th quarter worth $143,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Activity at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 2,368 shares of the stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $24.72, for a total transaction of $58,536.96. Following the completion of the transaction, the insider now owns 62,629 shares of the company’s stock, valued at $1,548,188.88. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Daniel Bradbury sold 23,323 shares of the firm’s stock in a transaction on Monday, May 6th. The stock was sold at an average price of $24.64, for a total transaction of $574,678.72. Following the completion of the transaction, the director now directly owns 9,981 shares in the company, valued at $245,931.84. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Derek J. Maetzold sold 2,368 shares of the business’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $24.72, for a total value of $58,536.96. Following the completion of the sale, the insider now owns 62,629 shares in the company, valued at approximately $1,548,188.88. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,059 shares of company stock worth $688,627. Company insiders own 7.20% of the company’s stock.

Analyst Ratings Changes

Separately, Robert W. Baird reissued an “outperform” rating and issued a $34.00 price objective on shares of Castle Biosciences in a report on Friday, July 5th.

Castle Biosciences Trading Up 9.1 %

CSTL traded up $1.75 during trading hours on Friday, reaching $21.06. The company’s stock had a trading volume of 498,401 shares, compared to its average volume of 388,066. The stock has a market cap of $581.47 million, a PE ratio of -18.31 and a beta of 0.93. Castle Biosciences, Inc. has a fifty-two week low of $12.07 and a fifty-two week high of $25.91. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.25 and a quick ratio of 9.02. The business’s 50-day moving average is $21.61 and its 200-day moving average is $21.74.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.28. The business had revenue of $72.97 million for the quarter, compared to analyst estimates of $68.34 million. Castle Biosciences had a negative return on equity of 7.91% and a negative net margin of 12.28%. As a group, equities research analysts predict that Castle Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.